Education
About Us
Working with TipRanks
Follow Us
4DMedical Ltd (AU:4DX)
ASX:4DX
4DX Stock Chart & Stats
AU$3.52
<AU$0.01(1.02%)
At close: 4:00 PM EST
AU$3.52
<AU$0.01(1.02%)
Day’s Range― - ―
52-Week RangeAU$0.23 - AU$5.42
Previous CloseN/A
Volume497.15K
Average Volume (3M)10.77M
Market Cap
AU$2.01B
Enterprise ValueAU$2.00B
Total Cash (Recent Filing)AU$6.88M
Total Debt (Recent Filing)AU$4.31M
Price to Earnings (P/E)―
Beta2.11
Next Earnings
Mar 04, 2026EPS Estimate
-0.04Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.11
Shares Outstanding570,191,200
10 Day Avg. Volume5,850,211
30 Day Avg. Volume10,774,582
Financial Highlights & Ratios
PEG Ratio-0.06
Price to Book (P/B)0.80
Price to Sales (P/S)8.81
P/FCF Ratio-1.49
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
AU$3.85Price Target Upside9.38% Upside
Rating ConsensusHold
Number of Analyst Covering2
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Proprietary XV Lung-imaging Platform4DMedical’s XV Technology is a proprietary, clinically oriented imaging platform that converts CT data into quantitative lung ventilation and perfusion metrics. That technical moat supports durable adoption by radiology and pulmonology groups, anchoring long-term product differentiation and uptake across hospitals and trials.
Recurring Software And Services Revenue ModelThe company’s mix of software licensing/subscriptions, per-scan fees and services creates multiple recurring and usage-linked revenue streams. This business model supports predictable renewal opportunities and scaling with scan volume, which helps revenue durability as clinical adoption and installed base expand.
Conservative Leverage And Stable Equity BaseA low debt-to-equity profile and stable equity ratio provide financial flexibility, reducing refinancing risk and preserving runway for R&D and commercialization. For a growth-stage medical software company, conservative leverage supports investments in regulatory, clinical and sales initiatives without immediate solvency pressure.
Bears Say
Negative Operating And Free Cash FlowSustained negative operating and free cash flows indicate the company is burning cash to fund operations and growth. Over the medium term this pressures liquidity and may necessitate external financing, which can dilute shareholders or constrain investment timing for sales expansion and regulatory activities.
Persistent Net Losses And Weak ProfitabilityOngoing net losses and negative EBIT margins show operating costs outpace revenue, limiting ability to self-fund growth. Even with strong gross margins, elevated operating expenses for commercialization and R&D can keep profitability distant absent sustained revenue scale or substantial cost reductions.
Reported Decline In Revenue GrowthA reported year-over-year revenue decline signals challenges in customer additions, utilization, or pricing traction during commercialization. For a software-driven medical device firm, negative revenue trends erode operating leverage and extend the timeline to achieve break-even and positive cash generation.
4DMedical Ltd News
4DX FAQ
What was 4DMedical Ltd’s price range in the past 12 months?
4DMedical Ltd lowest share price was AU$0.23 and its highest was AU$5.42 in the past 12 months.
What is 4DMedical Ltd’s market cap?
4DMedical Ltd’s market cap is AU$2.01B.
When is 4DMedical Ltd’s upcoming earnings report date?
4DMedical Ltd’s upcoming earnings report date is Mar 04, 2026 which is in 16 days.
How were 4DMedical Ltd’s earnings last quarter?
4DMedical Ltd released its earnings results on Aug 28, 2025. The company reported -AU$0.109 earnings per share for the quarter, missing the consensus estimate of N/A by -AU$0.109.
Is 4DMedical Ltd overvalued?
According to Wall Street analysts 4DMedical Ltd’s price is currently Undervalued.
Does 4DMedical Ltd pay dividends?
4DMedical Ltd does not currently pay dividends.
What is 4DMedical Ltd’s EPS estimate?
4DMedical Ltd’s EPS estimate is -0.04.
How many shares outstanding does 4DMedical Ltd have?
4DMedical Ltd has 570,191,200 shares outstanding.
What happened to 4DMedical Ltd’s price movement after its last earnings report?
4DMedical Ltd reported an EPS of -AU$0.109 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 18.75%.
Which hedge fund is a major shareholder of 4DMedical Ltd?
Currently, no hedge funds are holding shares in AU:4DX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
4DMedical Ltd Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
AU$3.85 (9.38% Upside)
AU$3.85 (9.38% Upside)
Blogger Sentiment
Bullish
AU:4DX Sentiment 90%
Sector Average ―
Sector Average ―
Insider Transactions
Sold Shares
Worth AU$9.6M over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
205.21%
12-Months-Change
Fundamentals
Return on Equity
-44.49%
Trailing 12-Months
Asset Growth
-21.00%
Trailing 12-Months
Company Description
4DMedical Ltd
4DMedical Limited operates as a medical technology company in Australia and the United States. It commercializes XV Technology, a four-dimensional lung imaging technology. The company also offers software as a service delivery model; XV lung ventilation analysis software; Permetium, a preclinical imaging system which quantify regional changes in pulmonary function; and AccuVent 200, a small animal ventilator. The company was incorporated in 2012 and is based in Carlton, Australia.
4DX Stock 12 Month Forecast
Average Price Target
AU$3.85
▲(9.38% Upside)
Technical Analysis
Impedimed Limited
―
Cyclopharm Limited
―
Micro-X Ltd.
―
Aroa Biosurgery Ltd
―
EMvision Medical Devices Ltd.
―
Options Prices
Currently, No data available
---